355 related articles for article (PubMed ID: 31537411)
1. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
Jiang S; Zhen H; Jiang H
Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
[TBL] [Abstract][Full Text] [Related]
2. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
[TBL] [Abstract][Full Text] [Related]
3. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
Major A; Smith DE; Ghosh D; Rabinovitch R; Kamdar M
Cancer; 2020 Jan; 126(1):189-201. PubMed ID: 31509235
[TBL] [Abstract][Full Text] [Related]
4. Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
Neeman Y; Perry C; Silverman B; Waintraub N; Avivi I
Leuk Lymphoma; 2020 Nov; 61(11):2638-2644. PubMed ID: 32611210
[TBL] [Abstract][Full Text] [Related]
5. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors.
De Sanctis V; Alfò M; Di Rocco A; Ansuinelli M; Russo E; Osti MF; Valeriani M; Minniti G; Grapulin L; Musio D; Bracci S; Spagnoli A; Moleti ML; Tombolini V; Martelli M
Hematol Oncol; 2017 Dec; 35(4):554-560. PubMed ID: 28078727
[TBL] [Abstract][Full Text] [Related]
6. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma.
Geurts YM; Neppelenbroek SIM; Aleman BMP; Janus CPM; Krol ADG; van Spronsen DJ; Plattel WJ; Roesink JM; Verschueren KMS; Zijlstra JM; Koene HR; Nijziel MR; Schimmel EC; de Jongh E; Ong F; Te Boome LCJ; van Rijn RS; Böhmer LH; Ta BDP; Visser HPJ; Posthuma EFM; Bilgin YM; Muller K; van Kampen D; So-Osman C; Vermaat JSP; de Weijer RJ; Kersten MJ; van Leeuwen FE; Schaapveld M
ESMO Open; 2024 Feb; 9(2):102248. PubMed ID: 38350338
[TBL] [Abstract][Full Text] [Related]
7. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
8. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
Shaw J; Harvey C; Richards C; Kim C
Leuk Lymphoma; 2019 Dec; 60(13):3235-3243. PubMed ID: 31185769
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
[TBL] [Abstract][Full Text] [Related]
10. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark.
Jakobsen LH; Øvlisen AK; Severinsen MT; Bæch J; Kragholm KH; Glimelius I; Gang AO; Jørgensen JM; Frederiksen H; Poulsen CB; Clausen MR; Pedersen PT; Pedersen RS; Torp-Pedersen C; Eloranta S; El-Galaly TC
Blood Cancer J; 2022 Jan; 12(1):16. PubMed ID: 35087026
[TBL] [Abstract][Full Text] [Related]
11. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
12. Primary diffuse large B-cell lymphoma of the uterus: A SEER database analysis.
Ensor AM; Sanchez CG; Ensor JE; Anand K
Medicine (Baltimore); 2021 Oct; 100(40):e27359. PubMed ID: 34622835
[TBL] [Abstract][Full Text] [Related]
13. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.
Herr MM; Schonfeld SJ; Dores GM; Engels EA; Tucker MA; Curtis RE; Morton LM
Blood Adv; 2019 Jul; 3(13):1961-1969. PubMed ID: 31262739
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
Lee JW; Oh D; Eom KY; Kim JH; Kim WC; Chung MJ; Lee JH
Clin Exp Metastasis; 2020 Feb; 37(1):125-131. PubMed ID: 31555945
[TBL] [Abstract][Full Text] [Related]
15. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
16. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
17. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
Howlader N; Mariotto AB; Besson C; Suneja G; Robien K; Younes N; Engels EA
Cancer; 2017 Sep; 123(17):3326-3334. PubMed ID: 28464214
[TBL] [Abstract][Full Text] [Related]
18. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
19. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
20. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
